Abstract
The association between obesity and multiple myeloma risk may be partly attributed to reduced circulating levels of adiponectin in obese individuals. To prospectively evaluate multiple myeloma risk in relation to adiponectin levels overall and stratified by body mass index and other characteristics, we conducted a pooled investigation of pre-diagnosed peripheral blood samples from 624 multiple myeloma cases and 1,246 individually matched controls from seven cohorts participating in the Multiple Myeloma Cohort Consortium. Analysis of circulating analyte levels measured by ELISA revealed that higher total adiponectin levels were associated with reduced multiple myeloma risk overall [highest quartile vs. lowest: OR, 0.64; 95% confidence interval (CI) 0.47-0.85; Ptrend = 0.001]. This association was apparent among cases diagnosed six or more years after blood collection (OR, 0.60; 95% CI, 0.40-0.90; Ptrend = 0.004) and was similar in magnitude for men and women (OR, 0.59 and 0.66, respectively). Interestingly, we observed strong associations among subjects who were overweight (OR, 0.41; 95% CI, 0.26-0.65) or obese (OR, 0.41; 95% CI, 0.17-0.98) but not among those with normal weight (OR, 1.20; 95% CI, 0.73-2.00; overweight/obese vs. normal weight, Pinteraction = 0.04). Our findings provide the strongest epidemiologic evidence to date that adiponectin protects against multiple myeloma development, particularly among overweight and obese individuals, and offer a method for risk assessment in this susceptible population of heavier patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1935-1941 |
| Number of pages | 7 |
| Journal | Cancer Research |
| Volume | 76 |
| Issue number | 7 |
| DOIs | |
| State | Published - Apr 1 2016 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Low levels of circulating adiponectin are associated with multiple myeloma risk in overweight and obese individuals. / Hofmann, Jonathan N.; Birmann, Brenda M.; Teras, Lauren R.; Pfeiffer, Ruth M.; Wang, Ye; Albanes, Demetrius; Baris, Dalsu; Colditz, Graham A.; De Roos, Anneclaire J.; Giles, Graham G.; Hosgood, Howard D.; Lan, Qing; Landgren, Ola; Liao, Linda M.; Rothman, Nathaniel; Weinstein, Stephanie J.; Pollak, Michael N.; Neuhouser, Marian L.; Purdue, Mark P.
In: Cancer Research, Vol. 76, No. 7, 01.04.2016, p. 1935-1941.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Low levels of circulating adiponectin are associated with multiple myeloma risk in overweight and obese individuals
AU - Hofmann, Jonathan N.
AU - Birmann, Brenda M.
AU - Teras, Lauren R.
AU - Pfeiffer, Ruth M.
AU - Wang, Ye
AU - Albanes, Demetrius
AU - Baris, Dalsu
AU - Colditz, Graham A.
AU - De Roos, Anneclaire J.
AU - Giles, Graham G.
AU - Hosgood, Howard D.
AU - Lan, Qing
AU - Landgren, Ola
AU - Liao, Linda M.
AU - Rothman, Nathaniel
AU - Weinstein, Stephanie J.
AU - Pollak, Michael N.
AU - Neuhouser, Marian L.
AU - Purdue, Mark P.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - The association between obesity and multiple myeloma risk may be partly attributed to reduced circulating levels of adiponectin in obese individuals. To prospectively evaluate multiple myeloma risk in relation to adiponectin levels overall and stratified by body mass index and other characteristics, we conducted a pooled investigation of pre-diagnosed peripheral blood samples from 624 multiple myeloma cases and 1,246 individually matched controls from seven cohorts participating in the Multiple Myeloma Cohort Consortium. Analysis of circulating analyte levels measured by ELISA revealed that higher total adiponectin levels were associated with reduced multiple myeloma risk overall [highest quartile vs. lowest: OR, 0.64; 95% confidence interval (CI) 0.47-0.85; Ptrend = 0.001]. This association was apparent among cases diagnosed six or more years after blood collection (OR, 0.60; 95% CI, 0.40-0.90; Ptrend = 0.004) and was similar in magnitude for men and women (OR, 0.59 and 0.66, respectively). Interestingly, we observed strong associations among subjects who were overweight (OR, 0.41; 95% CI, 0.26-0.65) or obese (OR, 0.41; 95% CI, 0.17-0.98) but not among those with normal weight (OR, 1.20; 95% CI, 0.73-2.00; overweight/obese vs. normal weight, Pinteraction = 0.04). Our findings provide the strongest epidemiologic evidence to date that adiponectin protects against multiple myeloma development, particularly among overweight and obese individuals, and offer a method for risk assessment in this susceptible population of heavier patients.
AB - The association between obesity and multiple myeloma risk may be partly attributed to reduced circulating levels of adiponectin in obese individuals. To prospectively evaluate multiple myeloma risk in relation to adiponectin levels overall and stratified by body mass index and other characteristics, we conducted a pooled investigation of pre-diagnosed peripheral blood samples from 624 multiple myeloma cases and 1,246 individually matched controls from seven cohorts participating in the Multiple Myeloma Cohort Consortium. Analysis of circulating analyte levels measured by ELISA revealed that higher total adiponectin levels were associated with reduced multiple myeloma risk overall [highest quartile vs. lowest: OR, 0.64; 95% confidence interval (CI) 0.47-0.85; Ptrend = 0.001]. This association was apparent among cases diagnosed six or more years after blood collection (OR, 0.60; 95% CI, 0.40-0.90; Ptrend = 0.004) and was similar in magnitude for men and women (OR, 0.59 and 0.66, respectively). Interestingly, we observed strong associations among subjects who were overweight (OR, 0.41; 95% CI, 0.26-0.65) or obese (OR, 0.41; 95% CI, 0.17-0.98) but not among those with normal weight (OR, 1.20; 95% CI, 0.73-2.00; overweight/obese vs. normal weight, Pinteraction = 0.04). Our findings provide the strongest epidemiologic evidence to date that adiponectin protects against multiple myeloma development, particularly among overweight and obese individuals, and offer a method for risk assessment in this susceptible population of heavier patients.
UR - http://www.scopus.com/inward/record.url?scp=84963768563&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963768563&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-15-2406
DO - 10.1158/0008-5472.CAN-15-2406
M3 - Article
C2 - 26921332
AN - SCOPUS:84963768563
VL - 76
SP - 1935
EP - 1941
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 7
ER -